AI assistant
Novacyt Director's Dealing 2026
1557_rns_2026-03-30_4449a9f5-f8df-484b-9c4f-6a16db83bc44.pdf
Director's Dealing
Open in viewerOpens in your device viewer
NOVACYT
Avertissement aux actionnaires:
Une version en français de ce document sera publiée dès que possible.
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Paris, France, and Manchester, UK – 30 March 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has been notified that, on 26 and 27 March 2026, the following Directors purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):
| Director | Title | Number of Ordinary Shares purchased | Average price paid per Ordinary Share | Resultant beneficial holding | % of issued share capital |
|---|---|---|---|---|---|
| Lyn Rees | CEO | 73,379 | €0.3899 | 73,379 | 0.00% |
| John Brown | Chairman | 73,762 | €0.3899 | 73,762 | 0.00% |
| Ian Gilham | NED | 28,750 | £0.34415 | 28,750 | 0.00% |
Contacts
Novacyt SA
Lyn Rees, Chief Executive Officer
Steve Gibson, Chief Financial Officer
https://novacyt.com/investors
Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Singer Capital Markets (Joint Broker)
Phil Davies / James Fischer / Samed Ethemi
+44 (0) 20 7496 3000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
[email protected] / [email protected]
Walbrook PR (Financial PR & IR)
Paul McManus / Lianne Applegarth
Alice Woodings
+44 (0)20 7933 8780 or [email protected]
+44 (0)7980 541 893 / +44 (0)7584 391 303
+44 (0)7407 804 654
NOVACYT
GROUP
An international molecular diagnostics company, providing a broad portfolio of clinical and research use only products, and instrumentation
PRIMER
DESIGN
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
- Ranger® Technology: automated DNA sample preparation and target enrichment technology
- genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only
Range of services for the life sciences industry:
- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries, including Australia, following the recent acquisition of Southern Cross Diagnostics in March 2026, which has opened new distribution channels to the life sciences and diagnostics industries in the territory and the wider Asia-Pacific region. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||
|---|---|---|---|
| a) | Name | ||
| 1) Lyn Rees | |||
| 2) John Brown | |||
| 3) Ian Gilham | 1) CEO | ||
| 2) Chairman | |||
| 3) NED | |||
| 2. | Reason for the Notification | ||
| a) | Position/status | See 1(a) - classified as a PDMR of the Company | |
| b) | Initial notification/ Amendment | Initial Notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Novacyt S.A. | |
| b) | LEI | 213800BWAC2BF295EG28 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each | |
| Identification code | FR0010397232 | ||
| b) | Nature of the transaction | Acquisition of Ordinary Shares | |
| c) | Price(s) and volume(s) | ||
| 1) Lyn Rees | |||
| 2) John Brown | |||
| 3) Ian Gilham | Price | ||
| Volume | |||
| €0.3817 | |||
| 15,149 | |||
| €0.3919 | |||
| 56,438 | |||
| €0.3945 | |||
| 1,792 |
Price
Volume
€0.3817
15,228
€0.3919
56,732
€0.3950
1,802
Price
Volume
£0.34415
28,750 | |
| d) | Aggregated information:
· Aggregated volume
· Price
1) Lyn Rees
2) John Brown
3) Ian Gilham | Price
Volume
€0.3899
73,379
Price
Volume
€0.3899
73,762
Price
Volume
£0.34415
28,750 | |
| e) | Date of the transaction | 1 & 2) 26 and 27 March 2026
3) 27 March 2026 | |
| f) | Place of the transaction | 1 & 2) Euronext and 3) AIM | |